Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL LIVER FIBROSIS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL LIVER FIBROSIS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL LIVER FIBROSIS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
5.3 GLOBAL LIVER FIBROSIS MARKET ANALYSIS
6 EPIDEMOLOGY
6.1 EPIDEMOLOGY OF LIVER FIBROSIS
7 INDUSTRY INSIGHTS
7.1 DEMOGRAPHIC TRENDS
7.2 KEY PRICING STRATEGIES
7.3 KEY PATIENT ENROLLMENT STRATEGIES
7.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7.5 OTHER KOL SNAPSHOTS
8 REGULATORY FRAMWORK
9 PIPELINE ANALYSIS
9.1 PHASE III CANDIDATES
9.2 PHASE II CANDIDATES
9.3 PHASE I CANDIDATES
9.4 OTHERS (PRE-CLINICAL AND RESEARCH)
10 GLOBAL LIVER FIBROSIS MARKET, BY PRODUCT TYPE
10.1 OVERVIEW
(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB SEGMENTS)
10.2 DIAGNOSIS
10.2.1 NON SURGICAL TESTS
10.2.1.1. TRANSIENT ELASTOGRAPHY
10.2.1.1.1. ULTRASOUND ELASTOGRAPHY
10.2.1.1.2. MR ELASTOGRAPHY (MRE),
10.2.1.1.3. CT PERFUSION
10.2.1.2. BLOOD TESTS
10.2.1.2.1. ALANINE TRANSAMINASE (ALT) ENZYME TEST
10.2.1.2.2. ASPARTATE TRANSAMINASE (AST) ENZYME TEST
10.2.1.2.3. NAFLD-FIBROSIS SCORE
10.2.1.2.4. ENHANCED LIVER FIBROSIS (ELF) TEST
10.2.1.2.5. FIBROMETER
10.2.1.2.6. FIBROTEST
10.2.2 LIVER BIOPSY
10.2.3 OTHERS
10.3 TREATMENT
10.3.1 ACE INHIBITORS
10.3.1.1. BENAZEPRIL
10.3.1.2. LISINOPRIL
10.3.1.3. RAMIPRIN
10.3.2 NON-ALCOHOLIC STEATOHEPATITIS
10.3.2.1. OBETICHOLIC ACID
10.3.2.2. ARAMCHOL
10.3.2.3. SAROGLITAZAR
10.3.3 HEPATOTROPIC DRUG
10.3.3.1. EPCLUSA
10.3.3.2. HARVONI
10.3.3.3. MAYVRET
10.3.4 ANTIFIBROTICS
10.3.4.1. ANTI-INFLAMMATORIES
10.3.4.1.1. BELAPECTIN
10.3.4.1.2. CENICRIVIROC,
10.3.4.1.3. LIRAGLUTIDE
10.3.4.2. HEPATOCYTE APOPTOSIS INHIBITORS
10.3.4.2.1. EMRICASAN
10.3.4.2.2. PENTOXIFYLLINE
10.3.4.2.3. SELONSERTIB
10.3.4.2.4. OXIDATIVE STRESS INHIBITORS
10.3.4.2.5. METHYL FERULIC ACID
10.3.4.2.6. LOSARTAN
10.3.4.3. HEPATIC STELLATE CELL (HSC) INHIBITORS
10.3.5 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR)-ALPHA AGONIST
10.3.6 OTHERS
11 GLOBAL LIVER FIBROSIS MARKET, BY STAGES
11.1 OVERVIEW
11.2 F0
11.3 F1
11.4 F2
11.5 F3
11.6 F4
12 GLOBAL LIVER FIBROSIS MARKET, BY CONDITION
12.1 OVERVIEW
12.2 CHRONIC LIVER DISEASES
12.3 HEPATITIS C
12.4 NONALCOHOLIC STEATOHEPATITIS
13 GLOBAL LIVER FIBROSIS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.3 PARENTERAL
13.4 OTHERS
14 GLOBAL LIVER FIBROSIS MARKET, BY GENDER
14.1 OVERVIEW
14.2 MALE
14.2.1 AGE BELOW 4O YRS
14.2.2 40-55 YRS
14.2.3 ABOVE 55 YRS
14.3 FEMALE
14.3.1 AGE BELOW 4O YRS
14.3.2 40-55 YRS
14.3.3 ABOVE 55 YRS
15 GLOBAL LIVER FIBROSIS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 CLINICS
15.5 AMBULATORY AND RESEARCH CENTERS
15.6 OTHERS
16 GLOBAL LIVER FIBROSIS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.3.1 HOSPITAL PHARMACY
16.3.2 RETAIL PHARMACY
16.3.3 ONLINE PHARMACY
17 GLOBAL LIVER FIBROSIS MARKET, BY REGION
17.1 GLOBAL LIVER FIBROSIS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
17.2 NORTH AMERICA
17.2.1 U.S.
17.2.2 CANADA
17.2.3 MEXICO
17.3 EUROPE
17.3.1 GERMANY
17.3.2 U.K.
17.3.3 ITALY
17.3.4 FRANCE
17.3.5 SPAIN
17.3.6 RUSSIA
17.3.7 SWITZERLAND
17.3.8 TURKEY
17.3.9 BELGIUM
17.3.10 NETHERLANDS
17.3.11 DENMARK
17.3.12 SWEDEN
17.3.13 POLAND
17.3.14 NORWAY
17.3.15 FINLAND
17.3.16 REST OF EUROPE
17.4 ASIA-PACIFIC
17.4.1 JAPAN
17.4.2 CHINA
17.4.3 SOUTH KOREA
17.4.4 INDIA
17.4.5 SINGAPORE
17.4.6 THAILAND
17.4.7 INDONESIA
17.4.8 MALAYSIA
17.4.9 PHILIPPINES
17.4.10 AUSTRALIA
17.4.11 NEW ZEALAND
17.4.12 VIETNAM
17.4.13 TAIWAN
17.4.14 REST OF ASIA-PACIFIC
17.5 SOUTH AMERICA
17.5.1 BRAZIL
17.5.2 ARGENTINA
17.5.3 REST OF SOUTH AMERICA
17.6 MIDDLE EAST AND AFRICA
17.6.1 SOUTH AFRICA
17.6.2 EGYPT
17.6.3 BAHRAIN
17.6.4 UNITED ARAB EMIRATES
17.6.5 KUWAIT
17.6.6 OMAN
17.6.7 QATAR
17.6.8 SAUDI ARABIA
17.6.9 REST OF MIDDLE EAST AND AFRICA
17.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
18 GLOBAL LIVER FIBROSIS MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18.5 MERGERS & ACQUISITIONS
18.6 NEW PRODUCT DEVELOPMENT & APPROVALS
18.7 EXPANSIONS
18.8 REGULATORY CHANGES
18.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
19 GLOBAL LIVER FIBROSIS MARKET, COMPANY PROFILE
19.1 ECHOSENS
19.1.1 COMPANY OVERVIEW
19.1.2 REVENUE ANALYSIS
19.1.3 GEOGRAPHIC PRESENCE
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 EITHEALTH
19.2.1 COMPANY OVERVIEW
19.2.2 REVENUE ANALYSIS
19.2.3 GEOGRAPHIC PRESENCE
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPEMENTS
19.3 VERTEX PHARMACEUTICALS INCORPORATED
19.3.1 COMPANY OVERVIEW
19.3.2 REVENUE ANALYSIS
19.3.3 GEOGRAPHIC PRESENCE
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPEMENTS
19.4 MADRIGAL PHARMACEUTICALS.
19.4.1 COMPANY OVERVIEW
19.4.2 REVENUE ANALYSIS
19.4.3 GEOGRAPHIC PRESENCE
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPEMENTS
19.5 HEPION PHARMACEUTICALS
19.5.1 COMPANY OVERVIEW
19.5.2 REVENUE ANALYSIS
19.5.3 GEOGRAPHIC PRESENCE
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPEMENTS
19.6 GALECTIN THERAPEUTICS
19.6.1 COMPANY OVERVIEW
19.6.2 REVENUE ANALYSIS
19.6.3 GEOGRAPHIC PRESENCE
19.6.4 PRODUCT PORTFOLIO
19.6.5 RECENT DEVELOPEMENTS
19.7 TAKEDA PHARMACEUTICAL COMPANY LIMITED
19.7.1 COMPANY OVERVIEW
19.7.2 REVENUE ANALYSIS
19.7.3 GEOGRAPHIC PRESENCE
19.7.4 PRODUCT PORTFOLIO
19.7.5 RECENT DEVELOPEMENTS
19.8 GENFIT
19.8.1 COMPANY OVERVIEW
19.8.2 REVENUE ANALYSIS
19.8.3 GEOGRAPHIC PRESENCE
19.8.4 PRODUCT PORTFOLIO
19.8.5 RECENT DEVELOPEMENTS
19.9 CONATUS PHARMACEUTICALS INC.
19.9.1 COMPANY OVERVIEW
19.9.2 REVENUE ANALYSIS
19.9.3 GEOGRAPHIC PRESENCE
19.9.4 PRODUCT PORTFOLIO
19.9.5 RECENT DEVELOPEMENTS
19.1 PHARMA HOLDINGS AS
19.10.1 COMPANY OVERVIEW
19.10.2 REVENUE ANALYSIS
19.10.3 GEOGRAPHIC PRESENCE
19.10.4 PRODUCT PORTFOLIO
19.10.5 RECENT DEVELOPEMENTS
19.11 INTERCEPT PHARMACEUTICALS, INC.
19.11.1 COMPANY OVERVIEW
19.11.2 REVENUE ANALYSIS
19.11.3 GEOGRAPHIC PRESENCE
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPEMENTS
19.12 XX
19.12.1 COMPANY OVERVIEW
19.12.2 REVENUE ANALYSIS
19.12.3 GEOGRAPHIC PRESENCE
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPEMENTS
19.13 ANIMA BIOTECH INC.
19.13.1 COMPANY OVERVIEW
19.13.2 REVENUE ANALYSIS
19.13.3 GEOGRAPHIC PRESENCE
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPEMENTS
19.14 GLYMPSE BIO.
19.14.1 COMPANY OVERVIEW
19.14.2 REVENUE ANALYSIS
19.14.3 GEOGRAPHIC PRESENCE
19.14.4 PRODUCT PORTFOLIO
19.14.5 RECENT DEVELOPEMENTS
19.15 ADALTA LIMITED
19.15.1 COMPANY OVERVIEW
19.15.2 REVENUE ANALYSIS
19.15.3 GEOGRAPHIC PRESENCE
19.15.4 PRODUCT PORTFOLIO
19.15.5 RECENT DEVELOPEMENTS
19.16 NOVOMEDIX
19.16.1 COMPANY OVERVIEW
19.16.2 REVENUE ANALYSIS
19.16.3 GEOGRAPHIC PRESENCE
19.16.4 PRODUCT PORTFOLIO
19.16.5 RECENT DEVELOPEMENTS
19.17 RECODE THERAPEUTICS
19.17.1 COMPANY OVERVIEW
19.17.2 REVENUE ANALYSIS
19.17.3 GEOGRAPHIC PRESENCE
19.17.4 PRODUCT PORTFOLIO
19.17.5 RECENT DEVELOPEMENTS
19.18 GALECTO, INC.
19.18.1 COMPANY OVERVIEW
19.18.2 REVENUE ANALYSIS
19.18.3 GEOGRAPHIC PRESENCE
19.18.4 PRODUCT PORTFOLIO
19.18.5 RECENT DEVELOPEMENTS
19.19 PLIANT THERAPEUTICS, INC.
19.19.1 COMPANY OVERVIEW
19.19.2 REVENUE ANALYSIS
19.19.3 GEOGRAPHIC PRESENCE
19.19.4 PRODUCT PORTFOLIO
19.19.5 RECENT DEVELOPEMENTS
19.2 INVERSAGO
19.20.1 COMPANY OVERVIEW
19.20.2 REVENUE ANALYSIS
19.20.3 GEOGRAPHIC PRESENCE
19.20.4 PRODUCT PORTFOLIO
19.20.5 RECENT DEVELOPEMENTS
19.21 F. HOFFMANN-LA ROCHE LTD
19.21.1 COMPANY OVERVIEW
19.21.2 REVENUE ANALYSIS
19.21.3 GEOGRAPHIC PRESENCE
19.21.4 PRODUCT PORTFOLIO
19.21.5 RECENT DEVELOPEMENTS
19.22 ASTRAZENECA
19.22.1 COMPANY OVERVIEW
19.22.2 REVENUE ANALYSIS
19.22.3 GEOGRAPHIC PRESENCE
19.22.4 PRODUCT PORTFOLIO
19.22.5 RECENT DEVELOPEMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
